Literature DB >> 17678831

Assessments in ankylosing spondylitis.

Jane Zochling1, Jürgen Braun.   

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease requiring regular medical care and monitoring to alleviate symptoms, maintain function, identify disease progression and initiate appropriate, timely therapies. Monitoring of the AS patient in clinical daily practice should not only include general history taking and physical examination, but also incorporate specific concepts, pertaining to the disease, which will aid in the detection of disease progression, the requirement of therapeutic intervention and the response to therapy. The Assessments in AS (ASAS) international working group has defined a core set of disease concepts that should be a part of everyday clinical record-keeping in AS, and has identified and validated measurement instruments corresponding to these health concepts, which can easily be incorporated into clinical practice. The group has also developed recommendations for management and a consensus statement for the use of biological therapies in AS, which includes recommendations for the monitoring of AS patients receiving these therapies. This chapter reviews the recommendations for monitoring AS patients in daily clinical practice, with particular regard to those receiving biological treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678831     DOI: 10.1016/j.berh.2007.02.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  17 in total

Review 1.  The treatment of psoriatic arthritis and inflammatory spondylitis.

Authors:  Hernan Castro-Rueda; Arthur Kavanaugh
Journal:  Curr Pain Headache Rep       Date:  2008-12

2.  Variation in fatigue may be poorly explained by pain: results from a longitudinal, exploratory study.

Authors:  Anne Christie; Hanne Dagfinrud; Petter Mowinckel; Kåre Birger Hagen
Journal:  Rheumatol Int       Date:  2015-09-08       Impact factor: 2.631

3.  Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.

Authors:  Ashit Syngle; Kanchan Vohra; Anjali Sharma; L Kaur
Journal:  Clin Rheumatol       Date:  2010-03-05       Impact factor: 2.980

4.  An exploration of the inter- and intra-rater reliability of the Bath Ankylosing Spondylitis Metrology Index.

Authors:  Jane H Martindale; Chris J Sutton; Lynne Goodacre
Journal:  Clin Rheumatol       Date:  2012-08-15       Impact factor: 2.980

5.  A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis.

Authors:  Muhammet Cinar; Sedat Yilmaz; Fatma Ilknur Cinar; Suleyman Serdar Koca; Hakan Erdem; Salih Pay; Ayhan Dinc; Yusuf Yazici; Ismail Simsek
Journal:  Rheumatol Int       Date:  2015-03-21       Impact factor: 2.631

6.  Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East.

Authors:  Bahiri Rachid; Bassel El Zorkany; Ehab Youseif; Mohammed Tikly
Journal:  Clin Rheumatol       Date:  2012-08-19       Impact factor: 2.980

7.  I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis in vivo and in vitro.

Authors:  Jianping Fan; Jian Zhao; Jie Shao; Xianzhao Wei; Xiaodong Zhu; Ming Li
Journal:  Exp Ther Med       Date:  2017-08-25       Impact factor: 2.447

8.  Spironolactone improves endothelial dysfunction in ankylosing spondylitis.

Authors:  Ashit Syngle; Kanchan Vohra; Dinesh Khichi; Nidhi Garg; Inderjeet Verma; Ladbans Kaur
Journal:  Clin Rheumatol       Date:  2013-03-16       Impact factor: 2.980

9.  Fatigue in patients with ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep disturbance.

Authors:  Rezzan Günaydin; Altinay Göksel Karatepe; Nesrin Ceşmeli; Taciser Kaya
Journal:  Clin Rheumatol       Date:  2009-06-07       Impact factor: 2.980

10.  The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra- and inter-rater agreements.

Authors:  O R Madsen; L B Hansen; A Rytter; C Suetta; C Egsmose
Journal:  Clin Rheumatol       Date:  2008-08-26       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.